A decade on, the German pharma giant is worth less than the $62 bln it paid for Roundup's maker. Known legal risks negated any promised benefits. The deal created value in one way: it flagged the power of disaster modeling and liability insurance to avoid similar pitfalls.
Aimee Donnellan is an Associate Editor at various esteemed publications. She specializes in topics related to banking, finance, and the economy, with a focus on capital markets, economic policy, and regional interests, particularly in LATAM and commodities. Aimee's work has been featured in Diario EL PAÍS, WAtoday, Regina Leader-Post, HELLENIC SHIPPING NEWS Worldwide, Air Mail, Reuters, Republic World, Reuters Breakingviews, bdnews24.com, and Magzter.












